Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Relay Therapeutics, Pfizer to Collaborate on Atirmociclib and RLY-2608 Clinical Trial
Details : The collaboration with Pfizer to evaluate atirmociclib, selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.
Brand Name : RLY-2608
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : RLY-2608,Atirmociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Pfizer Inc
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?